Showing results (31-40 of 167) with videos related to
Sort By:
Pageof 17
The Lancet. Oncology|January 4, 2014
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpointMatthew D Hellmann, Jamie E Chaft, William N William, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.Leukemia & Lymphoma|June 6, 2013
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory diseaseJacob D Soumerai, Matthew D Hellmann, Yang Feng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLCLaurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Clinical characteristics and course of 63 patients with BRAF mutant lung cancersAnya M Litvak, Paul K Paik, Kaitlin M Woo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2021
The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant TumorsNarek Shaverdian, Michael Offin, Annemarie F Shepherd, et al.Cancer Cell|June 21, 2024
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumorsGabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, et al.Plos One|August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumorsKathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.Journal of the National Cancer Institute|January 2, 2017
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + IpilimumabClaire F Friedman, Varina Clark, Andrew V Raikhel, et al.Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancerJamie E Chaft, Ibiayi Dagogo-Jack, Fernando C Santini, et al.Pageof 17